Cargando…
Blood-Brain Barrier in Drug Discovery : Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs.
Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery. Written by world experts to provide pract...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Hoboken :
Wiley,
2014.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Mi 4500 | ||
|---|---|---|---|
| 001 | EBOOKCENTRAL_ocn899941813 | ||
| 003 | OCoLC | ||
| 005 | 20240329122006.0 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 150110s2014 xx o 000 0 eng d | ||
| 040 | |a EBLCP |b eng |e pn |c EBLCP |d OCLCQ |d DEBSZ |d OCLCQ |d ZCU |d MERUC |d ICG |d OCLCF |d OCLCO |d OCLCQ |d OCLCO |d OCLCQ |d DKC |d AU@ |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d OCLCL | ||
| 020 | |a 9781118788547 | ||
| 020 | |a 1118788540 | ||
| 029 | 1 | |a DEBBG |b BV044072354 | |
| 029 | 1 | |a DEBSZ |b 431873445 | |
| 035 | |a (OCoLC)899941813 | ||
| 050 | 4 | |a QP375.5 .D384 2015 | |
| 082 | 0 | 4 | |a 612.82 |
| 049 | |a UAMI | ||
| 100 | 1 | |a Di, Li. | |
| 245 | 1 | 0 | |a Blood-Brain Barrier in Drug Discovery : |b Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs. |
| 260 | |a Hoboken : |b Wiley, |c 2014. | ||
| 300 | |a 1 online resource (607 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a Title Page; Copyright Page; Contents; Contributors; Preface; Chapter 1 Introduction and Overview; Restricted Brain Exposure Reduces CNS Drug Efficacy; Permitted CNS Access Increases Side Effects of Peripheral Drugs; A New Generation of CNS Exposure Tools; Case Studies of Drug Development Successes; Conclusion; Part 1 Pharmacokinetics of Brain Exposure; Chapter 2 Pharmacokinetics of CNS Penetration; Introduction; CNS Penetration; NeuroPK; Strategies to Increase/Avoid CNS Penetration/Exposure to Targets within the CNS; Translating NeuroPK from Animals to Humans; Summary and Outlook; References. | |
| 505 | 8 | |a Chapter 3 Free Drug Hypothesis for CNS Drug CandidatesIntroduction; Use of Brain Homogenate and Brain Slice Methods to Determine Unbound Brain Concentration; In vivo Pharmacokinetic/Pharmacodynamic Observations to Support Free Drug Hypothesis for CNS Drugs; Strategy to Increase Unbound Brain Concentration in CNS Drug Design; Reduction of Brain Tissue Binding Cannot Increase Unbound Brain Concentration; Kp Is a Misleading Parameter for the Assessment of Brain Penetration; Summary; References; Chapter 4 Species Differences and Impact of Disease State on BBB. | |
| 505 | 8 | |a The Need for a Better Understanding of CNS Drug DispositionThe Key Parameters Describing Drug Delivery into the Brain; Species Differences in Drug Delivery into the Brain; BBB Properties in Disease States; Conclusions; References; Part 2 Mechanisms of Drugs Across the Blood-Brain Barrier; Chapter 5 Passive Diffusion Permeability of the BBB-Examples and SAR; Introduction; Points to Consider for In Vitro-In Vivo Correlations; In Vitro Models and Measurements; Cell-Based Permeability Assays; In Vivo Models and Measurements; In Silico Models; Summary; References. | |
| 505 | 8 | |a Chapter 6 Establishment of P-Glycoprotein Structure-Transport Relationships to Optimize CNS Exposure in Drug DiscoveryTransport Models Surrogated for the Blood-Brain Barrier; P-gp Transport Mechanisms and Drug Properties; Establishment of SAR in Discovery Programs; Conclusions; References; Chapter 7 Uptake Transport at the BBB-Examples and SAR; Introduction; OATP1A2; OATP2B1; LAT; ENT1; MCT1; Discussion and Future Perspective; References; Chapter 8 Transport of Protein and Antibody Therapeutics across the Blood-Brain Barrier; Biotechnology and the Brain: Historical Perspective. | |
| 505 | 8 | |a Blood-Brain Barrier Molecular Trojan Horse TechnologyReengineering Recombinant Protein Therapeutics as IgG Fusion Proteins; IgG Fusion Proteins for Targeted BBB Delivery; Pharmacologic Effects in Mouse Models of Neural Disease; Reengineering Therapeutic Antibodies as BBB-Penetrating Bispecific Antibodies; Reengineering an Anti-Amyloid Antibody as a BBB-Penetrating Bispecific Antibody; Pharmacologic Effects in a Mouse Model of Alzheimer's Disease; Safety Pharmacology of Molecular Trojan Horse Fusion Proteins in Mice and Primates; Antidrug Antibody Response to IgG Fusion Proteins; Summary. | |
| 504 | |a References. | ||
| 520 | |a Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery. Written by world experts to provide practical solutions to increase brain penetration or minimize CNS side-effects Reviews state-of-the-art in silico, in vitro, and in vivo tools to assess brain penetration and advanced CNS drug delivery strategies Covers BBB physiology, medicinal chemistry design principles, free drug hypothesis for th. | ||
| 590 | |a ProQuest Ebook Central |b Ebook Central Academic Complete | ||
| 650 | 0 | |a Brain |x Effect of drugs on. | |
| 650 | 0 | |a Blood-brain barrier. | |
| 650 | 2 | |a Blood-Brain Barrier | |
| 650 | 6 | |a Cerveau |x Effets des médicaments sur. | |
| 650 | 6 | |a Barrière hémato-encéphalique. | |
| 650 | 7 | |a Blood-brain barrier |2 fast | |
| 650 | 7 | |a Brain |x Effect of drugs on |2 fast | |
| 700 | 1 | |a Kerns, Edward H. | |
| 758 | |i has work: |a Blood-brain barrier in drug discovery (Text) |1 https://id.oclc.org/worldcat/entity/E39PCFrJCQXkWFHjGw8JBkkvH3 |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Di, Li. |t Blood-Brain Barrier in Drug Discovery : Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs. |d Hoboken : Wiley, ©2014 |z 9781118788356 |
| 856 | 4 | 0 | |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=1895601 |z Texto completo |
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL1895601 | ||
| 994 | |a 92 |b IZTAP | ||